UnitedHealth shares slump — is the US healthcare industry in trouble?
The murder of UnitedHealthcare’s CEO has shone a spotlight on a struggling US healthcare industry with an inauspicious outlook


Shares in UnitedHealth slumped by 10% following the fatal shooting of UnitedHealthcare’s CEO Brian Thompson on 4 December. Many people were “indifferent” to the assassination, with the group’s business practices in the spotlight instead. Some lambasted the group for “placing greater emphasis on their bottom line [than] providing quality coverage to its insurees”. Some investors worry that UnitedHealth “will see reduced customer loyalty, resulting in worse financial performance”.
It’s not only UnitedHealth, which saw its market capitalisation fall by $55 billion, that is facing pressure, says Forbes’ Derek Saul. There has been a wider sell-off in health insurance shares with a range of companies, such as Elevance Health, Cigna, Centene and Humana all losing ground. The fear seems to be that the anti-insurer sentiment expressed by the public may pressure the industry “to adjust how they handle coverage decisions”. If companies don’t, they know that they might eventually “face the wrath of the public” in the form of increased regulation.
Thompson appears to have become “a proxy for the healthcare industry writ large”, says Bloomberg’s Lisa Jarvis. The big question is whether this rage is channelled into something useful, at a time when the incoming Trump administration “seems keen to find cuts in ways that will directly harm Americans’ access to care, whether by making insurance less affordable or through deep cuts to Medicaid”.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
For now, most analysts still expect the new administration to focus on “traditional Republican priorities”, such as trying to shift more patients into the privately administered programme known as Medicare Advantage, says David Wainer in The Wall Street Journal.
However, even under Trump, Republicans could be willing to pursue greater scrutiny on certain practices by insurers such as the requirement for a doctor to secure approval before providing a service, which the Biden administration had already “begun cracking down on”. At the very least, insurance executives could be forced to “tread more carefully when it comes to denying medical claims” in future.
Overall, something is very wrong with the US healthcare system, says Robert Cyran for Breakingviews – “only 5% of respondents ranked the services provided by health insurers as excellent in a 2023 Gallup poll, with about a third classifying them as poor”.
What’s more, despite the US spending $12,000 per head on healthcare, 2.5 times the average for countries in the Organisation for Economic Cooperation and Development, Americans still have “a lower life expectancy than most countries in the bloc”. Insurance premiums and out-of-pocket spending by individuals have also risen above inflation, with the US “spending more money and time on insurance, administration, patient paperwork, cost disputes and bickering over insurer approval for treatments”.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Matthew graduated from the University of Durham in 2004; he then gained an MSc, followed by a PhD at the London School of Economics.
He has previously written for a wide range of publications, including the Guardian and the Economist, and also helped to run a newsletter on terrorism. He has spent time at Lehman Brothers, Citigroup and the consultancy Lombard Street Research.
Matthew is the author of Superinvestors: Lessons from the greatest investors in history, published by Harriman House, which has been translated into several languages. His second book, Investing Explained: The Accessible Guide to Building an Investment Portfolio, is published by Kogan Page.
As senior writer, he writes the shares and politics & economics pages, as well as weekly Blowing It and Great Frauds in History columns He also writes a fortnightly reviews page and trading tips, as well as regular cover stories and multi-page investment focus features.
Follow Matthew on Twitter: @DrMatthewPartri
-
House prices rising fastest in areas with highest crime rates – where does your area rank?
Property prices are higher in safer areas but growing more slowly than in places benefiting from gentrification and buy-to-lets
-
State pension age review launched – could it rise faster in future?
The government has announced a review of the state pension age, after it warned of a “retirement crisis” and revived the Pensions Commission to boost pension savings
-
Zohran Mamdani wows New York – what did the mayoral candidate get right?
Zohran Mamdani, 33, has won the Democratic candidacy to be mayor of New York. That has energised his supporters and enemies alike – and terrified the rich
-
The new products and growth sectors driving America’s long-term winners
Opinion Felix Wintle, manager of the VT Tyndall North American Fund, highlights three favourite US stocks where he'd put his money
-
What will be the consequences of Donald Trump’s "One Big Beautiful Bill"?
The US president’s "One Big Beautiful Bill", an extraordinary mix of tax cuts and spending plans, has made it through both houses of the US Congress. What will be the consequences?
-
Tariffs 'were a terrible idea but shunning the US is a big mistake'
Opinion Manufacturers and investors have pivoted away from the US, the world’s biggest economy. That’s a mistake, says Matthew Lynn
-
Is Donald Trump putting the US dollar in danger?
Donald Trump's administration sees one of its greatest advantages – the US dollar – as a burden. Gold is the obvious beneficiary, says Cris Sholto Heaton.
-
US and China reach a ceasefire in their trade war after talks in London
The US and China's trading relationship – the most important one in the global economy – is back on track. Will the truce last?
-
Donald Trump has one last chance to avert a recession in the US
Opinion Trump's chaotic policymaking has hurt businesses’ confidence. The US president must get his act together to avoid a full-blown recession, says Matthew Lynn
-
'Ignore the gloom: US stocks are a buy'
Opinion The consensus says the age of American exceptionalism is over. But that is not the way to bet, says Max King